Craig Gulliford - Creo Medical CEO Director
| CREO Stock | 17.50 0.62 3.67% |
CEO
Craig Gulliford is CEO Director of Creo Medical Group
| Age | 54 |
| Address | Creo House, Chepstow, United Kingdom, NP16 5UH |
| Phone | 44 12 9160 6005 |
| Web | https://www.creomedical.com |
Creo Medical Management Efficiency
The company has return on total asset (ROA) of (0.201) % which means that it has lost $0.201 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3849) %, meaning that it generated substantial loss on money invested by shareholders. Creo Medical's management efficiency ratios could be used to measure how well Creo Medical manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Creo Medical's Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 40.6 M in 2024, whereas Total Current Assets are likely to drop slightly above 32.9 M in 2024.Similar Executives
| Found 5 records | CEO Age | ||
| Arne Mogster | Austevoll Seafood ASA | 49 | |
| Steven Quah | Aeorema Communications Plc | 60 | |
| Declan Morrissey | Roebuck Food Group | 36 | |
| Jeremy Wright | Virgin Wines UK | 55 | |
| Alexander Whitehouse | Premier Foods PLC | 55 | |
Management Performance
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.2 |
Creo Medical Group Leadership Team
Elected by the shareholders, the Creo Medical's board of directors comprises two types of representatives: Creo Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Creo. The board's role is to monitor Creo Medical's management team and ensure that shareholders' interests are well served. Creo Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Creo Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Phil Hales, Sales Director | ||
| Richard ACA, CFO Director | ||
| Richard Craven, Secretary | ||
| David Woods, Chief Director | ||
| Craig Gulliford, CEO Director | ||
| Pr Hancock, CTO Founder |
Creo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Creo Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (0.74) % | ||||
| Operating Margin | (0.89) % | ||||
| Current Valuation | 73.95 M | ||||
| Shares Outstanding | 412.15 M | ||||
| Shares Owned By Insiders | 20.44 % | ||||
| Shares Owned By Institutions | 49.98 % | ||||
| Price To Book | 1.47 X | ||||
| Price To Sales | 2.38 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Creo Stock Analysis
When running Creo Medical's price analysis, check to measure Creo Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Creo Medical is operating at the current time. Most of Creo Medical's value examination focuses on studying past and present price action to predict the probability of Creo Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Creo Medical's price. Additionally, you may evaluate how the addition of Creo Medical to your portfolios can decrease your overall portfolio volatility.